Evidence map›Paper›PMID 25965568›Full record

ArticleCancer cell2015

Defining the molecular landscape of ependymomas.

Tenley C Archer, Scott L Pomeroy

Abstract readComment
PubMed Publisher
In one paragraph

Article in Cancer cell, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Medulloblastoma: Molecular Classification-Based Personal Therapeutics.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2017
    Review
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Tenley C ArcherDepartment of Neurology, Boston Children's Hospital, Harvard Medical School, Harvard University, Cambridge, MA 02138, USA; Broad Institute of MIT and Harvard, Harvard University, Cambridge, MA 02138, USA.
Scott L PomeroyDepartment of Neurology, Boston Children's Hospital, Harvard Medical School, Harvard University, Cambridge, MA 02138, USA; Broad Institute of MIT and Harvard, Harvard University, Cambridge, MA 02138, USA. Electronic address: scott.pomeroy@childrens.harvard.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ependymomas have a variable prognosis. In this issue of Cancer Cell, Pajtler and colleagues identify nine subgroups of ependymoma using DNA methylation profiles. Two subgroups, predominately pediatric, are responsible for most of the mortality, with all others having nearly 100% overall survival after 5 years.

Indexed as

Age FactorsCentral Nervous System NeoplasmsEpendymomaFemaleHumansMale

Identifiers

PMID25965568

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.